Oncimmune Holdings PLC Successful £5.0m placing

Oncimmune Holdings PLC (LON:ONC), has today announced that, following the announcement made on 26 September 2017 entitled “Proposed Placing to raise up to £5.3 million”, the Company has raised a total of approximately £5.0 million (before expenses) by means of a conditional placing with new and existing investors of 4,166,667 Placing Shares at a price of 120 pence per share. Of this Placing, 3,333,334 ordinary shares (the “General Placing Shares”) will admit on 3 October 2017 and a further 833,333 Ordinary Shares (“Delayed Completion Placing Shares”) will admit within 5 business days of receipt of confirmation from HMRC that the Delayed Completion Placing Shares are regarded as a qualifying holding for the purposes of Part 6 of the Income Tax Act 2007 (the “VCT Condition”).

Assuming admission of both the General Placing Shares and the Delayed Completion Placing Shares, the Placing Shares will represent approximately 7.55% of the Company’s enlarged issued ordinary share capital.

It is expected that the VCT Condition will be fulfilled by the end of October as the Company has applied for, but not yet received advanced assurance from HM Revenues & Customs. However, there is no guarantee that the VCT Condition will be fulfilled. In the event that it is not fulfilled by the 24 November 2017, the Delayed Completion Placing will terminate and proceeds of the Delayed Completion Placing Shares will not be received.

Zeus Capital acted as Nominated Adviser and Broker to the Company.

Share capital on completion of the Placing

Application will be made for the General Placing Shares to be admitted to trading on AIM (“Initial Admission”). It is expected that Initial Admission will occur on or around 3 October 2017.

Following Initial Admission, the Company’s enlarged issued share capital will comprise 54,382,738 Ordinary Shares of 1 pence each with voting rights in the Company. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

Admission of the Delayed Completion Placing Shares is subject to satisfaction of the VCT Condition and will occur within 5 business days of satisfaction of the VCT Condition. An announcement will be made at that time confirming the timing of admission of the Delayed Completion Placing Shares.

Geoffrey-Hamilton Fairley, Oncimmune’s Chief Executive Officer said:

“This fundraise will allow us to continue to deliver on the growth strategy laid out at the time of our IPO involving generating revenue from multiple products, regions and partners and we have already made significant progress in delivering on this.  We are confident that Oncimmune is well placed to create and deliver value from our core autoantibody platform in the medium and long term.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The